Union Therapeutics licenses COVID-19 tech from TFF

By The Science Advisory Board staff writers

August 14, 2020 -- Union Therapeutics has completed an agreement with TFF Pharmaceuticals to obtain a worldwide exclusive license for the use of its thin film freezing technology in combination with niclosamide to focus on treatments for COVID-19.

The firm will pay TFF up to $210 million related to option exercise, development, and commercial milestones, as well as tiered single-digit royalties on product sales, according to a press release.

Why focus on niclosamide? The Institut Pasteur Korea recently identified niclosamide as a potent inhibitor of SARS-CoV-2. Union Therapeutics is conducting a phase I clinical trial of an optimized salt form of the compound developed as a potential inhalation treatment for COVID-19.

As for TFF, it has developed alternative oral and inhalation versions of niclosamide based on research from the University of Texas and its patented formulation technology. Under the agreement, Union Therapeutics will acquire an option to obtain a worldwide exclusive license to the technology and rights relating to the formulations of niclosamide for the treatment of COVID-19.

Because Union Therapeutics' Uni911 is already progressing through clinic development, the agreement with TFF has the potential to broaden Union Therapeutic's niclosamide product offering.

ANA Therapeutics to begin clinical trial for COVID-19 treatment
ANA Therapeutics said that the U.S. Food and Drug Administration has cleared its investigational new drug application for ANA001 (niclosamide capsules)...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter